High-rolling investors have positioned themselves bullish on Madrigal Pharmaceuticals (NASDAQ:MDGL), and it's important for retail traders to take note. \This activity came to our attention today ...
BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on the shares. The Q4 updates, which included “favorable” two-year OLE data, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback